Cantor Cuts Aravive to Neutral as Biotech Struggles to Stay in Business
Cantor Fitzgerald Downgrades Aravive to Neutral, Lowers Price Target to $0.25
Aravive Analyst Ratings
Aravive Analyst Ratings
The Latest Analyst Ratings for Aravive
Cantor Fitzgerald Reiterates Overweight on Aravive, Maintains $18 Price Target
Aravive Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Aravive, Maintains $18 Price Target
Aravive Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Aravive, Maintains $18 Price Target
The Latest Analyst Ratings for Aravive
Cantor Fitzgerald Reiterates Overweight on Aravive, Maintains $18 Price Target
EF Hutton Reiterates Buy on Aravive, Maintains $10 Price Target
Analysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Aravive (ARAV) and Cyclacel Pharmaceuticals (CYCC)
Analysts' Top Healthcare Picks: Annexon Biosciences (ANNX), Aravive (ARAV)
HC Wainwright & Co. Reiterates Buy on Aravive, Maintains $12 Price Target
Cantor Fitzgerald Reiterates Overweight on Aravive, Maintains $18 Price Target
EF Hutton Reiterates Buy on Aravive, Maintains $10 Price Target
HC Wainwright Raises Price Target on Aravive to $12 From $7, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Aravive (ARAV), Prelude Therapeutics (PRLD) and Mineralys Therapeutics, Inc. (MLYS)
No Data